Area under the curve of immunosuppressants.

<p>Area under the curve of immunosuppressants.</p

a, b, c Area under the curve of tacrolimus, MMF and prednisone over the study period from t₀ to t₆.

<p>a, b, c Area under the curve of tacrolimus, MMF and prednisone over the study period from t₀ to t₆.</p

Patient characteristics.

<p>Patient characteristics.</p

Gd-IgA1, total IgA1 and IgA-IgG complexes in recurrent and non-recurrent patients at t0, t3 and t6.

<p>Gd-IgA1, total IgA1 and IgA-IgG complexes in recurrent and non-recurrent patients at t0, t3 and t6.</p

a, b, and c. Changes of galactose-deficient IgA1, total IgA1 and IgA-IgG complexes over time under influence of changing degrees of immunosuppression with tacrolimus, mycophenolate mofetil (MMF) and prednisone.

<p>Boxes represent the median 50% of patients, lower and upper box ends are the 25th and 75th percentiles, and the middle bar represents the median. Whiskers link the lower/ upper box ends with the 5th and the 95th percentile. Outliers are represented by a closed circle.</p

Recipient, transplantation and donor qualitative characteristics at transplantation or at 1-year of transplantation of the training and validation samples (effective, standard deviation and missing values).

<p>Recipient, transplantation and donor qualitative characteristics at transplantation or at 1-year of transplantation of the training and validation samples (effective, standard deviation and missing values).</p

Calibration curves of the observed patient survival according to the predicted patient survival based on the 1-year RRS.

<p>(A) Patient survival was estimated from the DIVAT internal validation sample (n = 1148) at 4 years since the first anniversary of the transplantation. The sample was divided into 5 risk groups defined by the predicted patient survival. (B) Patient survival was estimated from the DIVAT internal validation sample (n = 1148) at 10 years since the first anniversary of the transplantation. The sample was divided into 5 risk groups. (C) Patient survival was estimated from the STCS cohort (n = 800) at 4 years since the first anniversary of the transplantation. The sample was divided into 3 risk groups since the number of deaths in the STCS cohort is low.</p

Results of the multivariable parametric survival model from the training sample (n = 2291).

<p>The scale and the shape parameters of the baseline Weibull hazard function were respectively equaled 2635.742 (SD = 0.671) and 1.318 (SD = 0.073).</p

Area under time-dependent ROC curves according to prognostic time to evaluate the prognostic capacities of the different markers.

<p>(A) The analyses were based on the DIVAT validation sample (n = 1148). The 1-year updated RRS (black continuous line, 10-year AUC = 0.78, 95%CI = [0.69, 0.85]). The RRS (black dashed line, 10-year AUC = 0.74, 95%CI = [0.66, 0.80]). The score proposed by Hernandez et al. (grey dotted line, 10-year AUC = 0.71, 95%CI = [0.64, 0.78]). The recipient age (grey dashed-dotted line, 10-year AUC = 0.71, 95%CI = [0.64, 0.77]). (B) The analyses were based on the STCS cohort (n = 800). The 1-year updated RRS (black continuous line, 4-year AUC = 0.77, 95%CI = [0.68, 0.85]). The RRS (black dashed line, 4-year AUC = 0.76, 95%CI = [0.66, 0.83]). The recipient age (grey dashed-dotted line, 4-year AUC = 0.69, 95%CI = [0.61, 0.76]).</p